"name","instanceType","label","description","uuid:ID","rationale","id"
"Study Design 1","StudyDesign","","The main design for the study","a358a0e6-5b91-4115-929c-346ebbe7683c","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1"
